Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Bernett

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Molecular Biology|January 5, 2010
Engineering fully human monoclonal antibodies from murine variable regionsMatthew J Bernett, Sher Karki, Gregory L Moore, et al.
The Journal of Allergy and Clinical Immunology|January 20, 2012
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibodySeung Y Chu, Holly M Horton, Erik Pong, et al.
Mabs|April 4, 2013
Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRnMatthew J Bernett, Seung Y Chu, Irene Leung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2019
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine ReleaseChristina L Zuch de Zafra, Flordeliza Fajardo, Wendy Zhong, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Frontiers in Pharmacology|June 18, 2024
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapyRajbharan Yadav, Suzanne Schubbert, Patrick G Holder, et al.
Cancer Discovery|October 20, 2023
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate CancerOlivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Molecular Biology|January 5, 2010
Engineering fully human monoclonal antibodies from murine variable regionsMatthew J Bernett, Sher Karki, Gregory L Moore, et al.
The Journal of Allergy and Clinical Immunology|January 20, 2012
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibodySeung Y Chu, Holly M Horton, Erik Pong, et al.
Mabs|April 4, 2013
Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRnMatthew J Bernett, Seung Y Chu, Irene Leung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2019
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine ReleaseChristina L Zuch de Zafra, Flordeliza Fajardo, Wendy Zhong, et al.
Blood|January 17, 2012
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector functionYu-Tzu Tai, Holly M Horton, Sun-Young Kong, et al.
Frontiers in Pharmacology|June 18, 2024
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapyRajbharan Yadav, Suzanne Schubbert, Patrick G Holder, et al.
Cancer Discovery|October 20, 2023
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate CancerOlivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Pageof 2